Monitoring the incidence of herpes zoster in Russia at the stage of implementing epidemiological surveillance


DOI: https://dx.doi.org/10.18565/epidem.2024.14.1.7-13

Afonina N.M., Mikheeva I.V.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
Objective. Epidemiological characteristics of herpes zoster (HZ) in the Russian Federation for justification of measures to improve epidemiological surveillance and prevention.
Materials and methods. Data from statistical observation form No. 2 and the «Department for Registration and Record of Infectious Disease (DRRID)» AIS system of the Center for Hygiene and Epidemiology in Moscow on the incidence of herpes zoster in the Russian Federation in 2019–2022 were studied. A correlation analysis between the incidence in the constituent entities of the Federation and the number of newly diagnosed cases of the disease caused by HIV was carried out, and the economic damage from HZ was assessed.
Results. Up to 19.5 thousand cases of the disease were registered annually in the Russian Federation. Average Russian incidence rates in 2019–2022. were 30–50 times lower than those of most foreign countries. The burden of disease varies among the constituent entities. In the age structure of the cases, more than 90% were adults. Cases of the disease are diagnosed in children, including those under the age of 1 year.
Conclusion. HZ is a significant problem for healthcare and the economy of the Russian Federation. In the absence of vaccine prophylaxis, the high incidence of HZ increases the risk of chickenpox infection.
Keywords: Varicella zoster virus, chickenpox, herpes zoster, epidemiological surveillance, morbidity, prevention
Read entire article

Literature

1. Лавров В.Ф., Свитич О.А., Казанова А.С., Кинкулькина А.Р., Зверев В.В. Varicella Zoster-вирусная инфекция: иммунитет, диагностика и моделирование in vivo. Журнал микробиологии, эпидемиологии и иммунобиологии. 2019; 96(4): 82–9. DOI: 10.36233/0372-9311-2019-4-82-89


Lavrov V.F., Svitich O.A., Kazanova A.S., Kinkulkina A.R., Zverev V.V. (Varicella Zoster virus infection: immunity, diagnosis and modelling in vivo). Journal of microbiology, epidemiology and immunobiology. 2019; 96(4): 82–9. (In Russ.). DOI: 10.36233/0372-9311-2019-4-82-89


2. Опоясывающий лишай (herpes zoster) у взрослых: Клинические рекамендации. М.: Национальное научное общество инфекционистов, 2014. http://nnoi.ru/uploads/files/protokoly/Herp_zoster.pdf?PHPSESSID= b4b3a19c8aed62caa9a6b51092987c56


(Herpes zoster in adults: Clinical guidelines). Moscow: National Scientific Society of Infectious Diseases, 2014. (In Russ.).


3. Gershon A., Marin M., Seward J.F. Varicella Vaccines. In: Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines. 7th ed. 2018: 1145–80. DOI:10.1016/B978-0-323-35761-6.00062-6


4. Ogunjimi B., Van den Bergh J., Meysman P., Heynderickx S., Bergs K. et al. Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox. Sci Rep. 2017; 7(1): 1–11. DOI:10.1038/s41598-017-01024-8


5. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infectious Diseases. 2004; (4): 26–33. DOI: 10.1016/s1473-3099(03)00857-0


6. Algaadi S.A. Herpes zoster and COVID-19 infection: a coincidence or a causal relationship? Infection 2021; 22: 1–5. DOI: 10.1007/s15010-021-01714-6


7. Namratha B.N., Navya S., Varala S., Krishna A.V. A case report of disseminated herpes zoster in association with COVID-19. Indian Dermatology Online Journal 2022; 13(2): 259–61. DOI: 10.4103/idoj.idoj_400_21


8. Yun S.H., Kim J., Hye-Rim Shin. A case report of Varicella Zoster meningitis as co-infection with breakthrough COVID- 19 in an immunocompetent patient. Journal of Korean Medical Science 2022; 28: 37–45. DOI: 10.3346/jkms.2022.37.e61


9. Varicella and herpes zoster vaccine: WHO position paper, 20 June 2014). Weekly Epidemiological Record, 2014; 89: 25 (full issue). https://www.who.int/immunization/position_papers/varicella_herpes_zoster_ vaccine_pp_ru_2014.pdf


10. Newman A.M., Jhaveri R. Myths and misconceptions: Varicella-Zoster virus exposure, infection risks, complications, and treatments. Clinical Therapeutics 2019; 41(9): 1816–22. DOI: 10.1016/j.clinthera.2019.06.009


11. Koshy E., Mengting Lu, Kumar H., Jianbo W. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. The Indian Journal of Dermatology, Venereology and Leprology 2018; 84(3): 251–62. DOI: 10.4103/ijdvl.IJDVL_1021_16


12. Lang P.O., Aspinall R. Vaccination for quality of life: herpes-zoster vaccine. Aging Clin Exp Res. 2021; 33(4): 1113–22. DOI: 10.1007/s40520-019-01374-5


13. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L, Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic proceedings. 2007; 82: 1341–9. DOI: 10.4065/82.11.1341


14. Leung J., Harpaz R., Molinari N.A., Jumaan A., Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin. Infect. Dis. 2011; 52(3): 332–40. DOI: 10.1093/cid/ciq077


15. Pan C.X., Lee M.S., Nambudiri V.E. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Therapeutic Advances in Vaccines and Immunotherapy 2022; 21: 1–19. DOI: 10.1177/25151355221084535


16. Jansen K., Haastert B., Michalik C., Guignard A., Esser S. Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis. BMC Infectious Diseases 2013; 13: 372–80. DOI: 10.1186/1471-2334-13-372


17. Marchetti S., Guzzetta G., Flem E., Mirinaviciute G., Scalia Tomba G., Manfred Р. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. Vaccine 2018; 36(8): 1116–25. DOI: 10.1016/j.vaccine.2018.01.038


18. Widgren K., Persson Berg L., Mörner A., Lindquist L, Tegnell A., Giesecke J. Severe chickenpox disease and seroprevalencein Sweden –implications for general vaccination. Int. Jl. Infect. Dis. 2021; 111: 92–8. DOI: 10.1016/j.ijid.2021.08.012


19. Widgren K., Tomba G.S., Leung K.Y., Giesecke J. Modelling varicella vaccination – What does a lack of surge in herpes zoster incidence tell us about exogenous boosting? Vaccine 2022; 40: 673–81. DOI: 10.1016/j.vaccine.2021.11.063


20. Каира А.Н., Лавров В.Ф. Опоясывающий герпес: эпидемиологические особенности заболеваемости в 2019 году. Эпидемиология и Вакцинопрофилактика 2020; 19(5): 93–7. DOI: 10.31631/2073-3046-2020-19-5-93-97


Kaira A.N., Lavrov V.F. (Herpes zoster: Epidemiological Features of the Incidence in 2019). Epidemiology and Vaccinal Prevention 2020; 19(5): 93–7. (In Russ.). DOI:10.31631/2073-3046-2020-19-5-93-97


21. Афонина Н.М., Михеева И.В. Социально-экономическая значимость инфекционной патологии, обусловленной вирусом Varicella zoster. Материалы XXI Конгресса педиатров России с международным участием «Актуальные проблемы педиатрии». М., 2019: 3.


Afonina N.M., Mikheeva I.V. (Socio-Economic Significance of Infectious Pathology Caused by the Varicella Zoster Virus). Abstracts of XXI Congress of Pediatricians of Russia With International Participation «Actual Problems of Pediatrics». Moscow, 2019: 3. (In Russ.).


22. Исаева М.С., Мирзоева М.Т., Олисова О.Ю., Кочер­гин Н.Г. Клинико-эпидемиологические особенности опоясывающего герпеса в Таджикистане. Российский журнал кожных и венерических болезней 2018; 21(2): 81–4. DOI: 10.18821/1560-9588-2018-21-2-81-84


Isaeva M.S., Mirzoeva M.T., Olisova O.Y., Kochergin N.G. (Clinical and epidemiological features of Herpes zoster in Tajik Republic). Russian Journal of Skin and Venereal Diseases 2018; 21(2): 81–4. (In Russ.). DOI: 10.18821/1560-9588-2018-21-2-81-84


23. Leung A.K., Robson W.L., Leong A.G. Herpes zoster in childhood. J. Pediatr. Health Care. 2006; 20(5): 300–3. DOI: 10.1016/j.pedhc.2006.01.004


24. Mandelbrot L. Fetal varicella – diagnosis, management, and outcome // Prenatal Diagnosis. 2012; 32 (6): 511–18. DOI: 10.1002/pd.3843


About the Autors

Nataliya M. Afonina, Cand. Med. Sci., Researcher, Laboratory of Immunization, Central Research Institute for Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; afonina_nat2009@mail.ru; http://orcid.org/0000-0002-3205-4025
Professor Irina V. Mikheeva, МD, Head, Laboratory of Immunoprophylaxis, Central Research Institute for Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; Irina_Mikheeva@mail.ru; http://orcid.org/0000-0001-8736-4007


Similar Articles

Back to Content

Бионика Медиа